Crizanlizumab parenteral
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Infusions of crizanlizumab.
These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.
Drugs List
Therapeutic Indications
Uses
Prevention of recurrent vaso-occlusive crises in sickle cell syndrome
Prophylaxis of recurrent vaso-occlusive crises in sickle cell patients aged 16 years and older either alone or with hydroxyurea or hydroxycarbamide.
Dosage
Adults
5mg/kg administered over 30 minutes at week 0, week 2 and every 4 weeks thereafter.
Children
Children aged 16 years and older
(See Dosage; Adult).
Additional Dosage Information
If crizanlizumab is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule. However, if crizanlizumab is administered more than 2 weeks after the missed dose, dosing should be continued every 4 weeks thereafter.
Administration
For intravenous infusion only.
Contraindications
Children under 16 years
Breastfeeding
Pregnancy
Precautions and Warnings
Severe renal impairment
Advise patient ability to drive or operate machinery may be impaired
Combination therapy: refer to information for concomitant agent
Treatment to be prescribed under the supervision of a specialist
Record name and batch number of administered product
Monitor patient for infusion-associated reactions (IARs)
May affect results of some laboratory tests
Interrupt treatment if severe infusion reaction occurs
Female: Ensure adequate contraception during treatment
Advise patient to seek medical advice if delayed adverse event(s) occurs
Pregnancy and Lactation
Pregnancy
Crizanlizumab is contraindicated during pregnancy.
The manufacturer recommends crizanlizumab is not used in pregnancy and in women of childbearing potential not using contraception. At the time of writing, human data is limited but animal studies have shown crizanlizumab has the potential to cause foetal losses when administered to a pregnant woman.
Lactation
Crizanlizumab is contraindicated during breastfeeding.
The manufacturer recommends that breastfeeding is discontinued during treatment with crizanlizumab. It is unknown if crizanlizumab is excreted in human milk but antibodies can be excreted in human milk. There are no data on the effects of crizanlizumab on the breast-fed infant or on milk production. A risk to neonates cannot be excluded.
Side Effects
Abdominal pain
Arthralgia
Back pain
Chest pain
Diarrhoea
Extravasation
Infusion related reaction
Infusion site pain
Infusion site reaction
Myalgia
Nausea
Oropharyngeal pain
Pruritus
Pyrexia
Swelling (injection site)
Vomiting
Vulvovaginal itching
Effects on Laboratory Tests
Crizanlizumab has been shown to interfere with automated platelet counts (platelet clumping) in particular when tubes containing ethylenediaminetetraacetic acid (EDTA) have been used. This has led to unevaluable or falsely decreased platelet counts. To mitigate the potential for laboratory test interference, it is recommended to run the test within 4 hours of blood collection or use citrate tubes. Platelet counts can be estimated via a peripheral blood smear when needed.
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: October 2021
Reference Sources
Summary of Product Characteristics: Adakveo 10mg/ml concentrate for solution for infusion. Novartis Pharmaceuticals UK Ltd. Revised July 2021.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 19 October 2021
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.